UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Advances in understanding the pathogenesis of graft‐versus‐host disease

British journal of haematology, 2016-04, Vol.173 (2), p.190-205

2016

Volltextzugriff (PDF)

Impact of a health information technology tool addressing information needs of caregivers of adult and pediatric hematopoietic stem cell transplantation patients

Supportive care in cancer, 2019-06, Vol.27 (6), p.2103-2112

2019

Volltextzugriff (PDF)

Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome

Leukemia research reports, 2022-01, Vol.17, p.100329-100329, Article 100329

2022

Volltextzugriff (PDF)

The Difficulties of Informed Consent in Stem Cell Transplant

Current hematologic malignancy reports, 2016-02, Vol.11 (1), p.1-5

2016

Volltextzugriff (PDF)

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients

Cancer cell, 2022-04, Vol.40 (4), p.340-342

2022

Volltextzugriff (PDF)

Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood, 2022-11, Vol.140 (Supplement 1), p.11020-11021

2022

Volltextzugriff (PDF)

Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems

Blood, 2022-11, Vol.140 (Supplement 1), p.6035-6036

2022

Volltextzugriff (PDF)

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

The New England journal of medicine, 2023-06, Vol.388 (25), p.2338-2348, Article 2338

2023

Volltextzugriff (PDF)

Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study

Blood, 2021-11, Vol.138 (Supplement 1), p.3414-3414

2021

Volltextzugriff (PDF)

Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy

Leukemia research, 2023-09, Vol.132, p.107348-107348, Article 107348

2023

Volltextzugriff (PDF)

Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database

Journal of the National Comprehensive Cancer Network, 2020-02, Vol.18 (2), p.169

2020

Volltextzugriff (PDF)

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Blood, 2022-11, Vol.140 (Supplement 1), p.157-158

2022

Volltextzugriff (PDF)

A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML

Blood, 2020-11, Vol.136 (Supplement 1), p.9-10

2020

Volltextzugriff (PDF)

A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)

Blood, 2021-11, Vol.138 (Supplement 1), p.2347-2347

2021

Volltextzugriff (PDF)

Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation

Bone marrow transplantation (Basingstoke), 2024-03, Vol.59 (3), p.373-379

2024

Volltextzugriff (PDF)

AML-530 Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S311-S311

2023

Volltextzugriff (PDF)

POSTER: AML-530 Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S168-S168

2023

Volltextzugriff (PDF)

Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results

Blood, 2018-11, Vol.132 (Supplement 1), p.2253-2253

2018

Volltextzugriff (PDF)

Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia

Leukemia research, 2022-12, Vol.123, p.106984, Article 106984

2022

Volltextzugriff (PDF)

Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.5083-5085

2022

Volltextzugriff (PDF)

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood, 2019-11, Vol.134 (Supplement_1), p.5068-5068

2019

Volltextzugriff (PDF)

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

Blood, 2019-11, Vol.134 (Supplement_1), p.2605-2605

2019

Volltextzugriff (PDF)

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Blood, 2019-11, Vol.134 (Supplement_1), p.5430-5430

2019

Volltextzugriff (PDF)

Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab

Autoimmunity reviews, 2013-09, Vol.12 (11), p.1085-1090

2013

Volltextzugriff (PDF)

A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.4401-4401

2021

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(52)
Buchkapitel
(2)

Sprache

Englisch
(54)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Hematology
(15)
Humans
(13)
Oncology
(11)
Transplantation
(9)
Immunology
(8)
Adult
(4)
Female
(4)
Male
(4)
Middle Aged
(4)
Stem Cell Transplantation
(4)
Aged
(3)
Allogeneic
(3)
Graft Vs Host Disease - Etiology
(3)
Gvhd
(3)
Hematopoietic Stem Cell Transplantation - Adverse Effects
(3)
Hematopoietic Stem Cell Transplantation - Methods
(3)
Hematopoietic Stem Cells
(3)
Retrospective Studies
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Advances in understanding the pathogenesis of graft‐versus‐host disease

Impact of a health information technology tool addressing information needs of caregivers of adult and pediatric hematopoietic stem cell transplantation patients

Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome

The Difficulties of Informed Consent in Stem Cell Transplant

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients

Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)

Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study

Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy

Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML

A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)

Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation

AML-530 Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy

POSTER: AML-530 Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy

Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results

Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia

Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab

A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma

Suchergebnisse filtern